Translocator protein (TSPO) ligands attenuate mitophagy deficits in the SH-SY5Y cellular model of Alzheimer's disease via the autophagy adaptor P62
Biochimie · 2024-09 · 224 · 132-138
DOI: 10.1016/j.biochi.2024.01.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochimie, 2024-09. Verfasst von Lauren H Fairley und 3 weiteren Autor:innen. Beteiligte Einrichtung: Research Cluster, Molecular & Cognitive Neuroscience, Neurobiology Laboratory for Brain Aging and Mental Health, University of Basel, Basel, Switzerl…. Hauptthemen laut MEDLINE: Mitophagy, Alzheimer Disease, Receptors, GABA, Sequestosome-1 Protein. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss State Secretariat for Education Research and Innovation.
Themen: Demenz
Abstract (Originalsprache)
Mitochondrial dysfunction has been widely implicated in the pathogenesis of Alzheimer's disease (AD), with accumulation of damaged and dysfunctional mitochondria occurring early in the disease. Mitophagy, which governs mitochondrial turnover and quality control, is impaired in the AD brain, and strategies aimed at enhancing mitophagy have been identified as promising therapeutic targets. The translocator protein (TSPO) is an outer mitochondrial membrane protein that is upregulated in AD, and ligands targeting TSPO have been shown to exert neuroprotective effects in mouse models of AD. However, whether TSPO ligands modulate mitophagy in AD has not been explored. Here, we provide evidence that the TSPO-specific ligands Ro5-4864 and XBD173 attenuate mitophagy deficits and mitochondrial fragmentation in a cellular model of AD overexpressing the human amyloid precursor protein (APP). Ro5-4864 and XBD173 appear to enhance mitophagy via modulation of the autophagic cargo receptor P62/SQSTM1, in the absence of an effect on PARK2, PINK1, or LC3 level. Taken together, these findings indicate that TSPO ligands may be promising therapeutic agents for ameliorating mitophagy deficits in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Cluster, Molecular & Cognitive Neuroscience, Neurobiology Laboratory for Brain Aging and Mental Health, University of Basel, Basel, Switzerland. Electronic address: lauren.fairley@uts.edu.au.
- Research Cluster, Molecular & Cognitive Neuroscience, Neurobiology Laboratory for Brain Aging and Mental Health, University of Basel, Basel, Switzerland; Psychiatric University Clinics, Basel, Switzerland.
- The MARCS Institute for Brain, Behaviour and Development, Western Sydney University, Australia.
Förderung
- Swiss State Secretariat for Education Research and Innovation
Zitieren
APA
Fairley, L. H., Grimm, A., Herff, S. A., & Eckert, A. (2024). Translocator protein (TSPO) ligands attenuate mitophagy deficits in the SH-SY5Y cellular model of Alzheimer's disease via the autophagy adaptor P62. Biochimie, 224, 132-138. https://doi.org/10.1016/j.biochi.2024.01.012
Vancouver
Fairley LH, Grimm A, Herff SA, Eckert A. Translocator protein (TSPO) ligands attenuate mitophagy deficits in the SH-SY5Y cellular model of Alzheimer's disease via the autophagy adaptor P62. Biochimie. 2024;224:132-138. doi:10.1016/j.biochi.2024.01.012
BibTeX
@article{Fairley2024,
author = {Fairley, Lauren H and Grimm, Amandine and Herff, Steffen A and Eckert, Anne},
title = {Translocator protein (TSPO) ligands attenuate mitophagy deficits in the SH-SY5Y cellular model of Alzheimer's disease via the autophagy adaptor P62},
journal = {Biochimie},
year = {2024},
volume = {224},
pages = {132--138},
doi = {10.1016/j.biochi.2024.01.012}
}
EUVIMED